These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 2516711)

  • 21. Malignant hyperthermia.
    Ben Abraham R; Adnet P; Glauber V; Perel A
    Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of otolaryngic patients susceptible to malignant hyperthermia without dantrolene.
    Derkay CS; Grundfast KM
    Otolaryngol Head Neck Surg; 1991 Nov; 105(5):680-6. PubMed ID: 1754251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Masseter muscle rigidity and malignant hyperthermia susceptibility.
    Rosenberg H; Fletcher JE
    Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia.
    Christiaens F; Gepts E; D'Haese J; Camu F
    Acta Anaesthesiol Belg; 1995; 46(2):93-7. PubMed ID: 8714856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Masseter spasm with anesthesia: incidence and implications.
    Schwartz L; Rockoff MA; Koka BV
    Anesthesiology; 1984 Dec; 61(6):772-5. PubMed ID: 6507932
    [No Abstract]   [Full Text] [Related]  

  • 27. Masseter muscle spasm in children: implications of continuing the triggering anesthetic.
    Littleford JA; Patel LR; Bose D; Cameron CB; McKillop C
    Anesth Analg; 1991 Feb; 72(2):151-60. PubMed ID: 1898685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant hyperthermia in Brazil: analysis of hotline activity in 2009.
    Almeida da Silva HC; dos Santos Almeida C; Mendes Brandão JC; Nogueira e Silva CA; Pinto de Lorenzo ME; Duarte Ferreira CB; Resende AH; Barreira SR; de Almeida PA; Cunha Ferraro LH; Takeda A; de Oliveira KF; Lelis TG; Hortense A; Perez MV; Schmidt B; Bulle Oliveira AS; Gomes do Amaral JL
    Braz J Anesthesiol; 2013; 63(1):13-9. PubMed ID: 23438798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suxamethonium, masseter spasm and later malignant hyperthermia.
    Ramirez JA; Cheetham ED; Laurence AS; Hopkins PM
    Anaesthesia; 1998 Nov; 53(11):1111-6. PubMed ID: 10023282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Abortive course of malignant hyperthermia following preclinical induction of general anesthesia using succinylcholine].
    Helf D; Schneiderbanger D; Markus CK; Johannsen S; Schuster F
    Anaesthesist; 2018 Apr; 67(4):275-279. PubMed ID: 29480319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.
    Chan TY; Bulger TF; Stowell KM; Gillies RL; Langton EE; Street NE; Pollock NA
    Anaesth Intensive Care; 2017 Nov; 45(6):707-713. PubMed ID: 29137581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suspected malignant hyperthermia reactions in New Zealand.
    Pollock AN; Langton EE; Couchman K; Stowell KM; Waddington M
    Anaesth Intensive Care; 2002 Aug; 30(4):453-61. PubMed ID: 12180584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Masseter muscle rigidity and nondepolarizing neuromuscular blocking agents.
    Albrecht A; Wedel DJ; Gronert GA
    Mayo Clin Proc; 1997 Apr; 72(4):329-32. PubMed ID: 9121179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs.
    Hackl W; Mauritz W; Schemper M; Winkler M; Sporn P; Steinbereithner K
    Br J Anaesth; 1990 Apr; 64(4):425-9. PubMed ID: 2334615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant Hyperthermia.
    Kaur H; Katyal N; Yelam A; Kumar K; Srivastava H; Govindarajan R
    Mo Med; 2019; 116(2):154-159. PubMed ID: 31040503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Williams syndrome: masseter spasm during anaesthesia.
    Patel J; Harrison MJ
    Anaesthesia; 1991 Feb; 46(2):115-6. PubMed ID: 1872423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant hyperthermia in the otolaryngologic patient: prospective anesthetic and surgical management of eight children.
    Dudley JP; Reynolds R; Dubrow TJ
    Ann Otol Rhinol Laryngol; 1990 Apr; 99(4 Pt 1):297-9. PubMed ID: 2327699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Masseter muscle rigidity and the role of DNA analysis to confirm malignant hyperthermia susceptibility.
    Hudig K; Pollock N; Bulger T; Machon RG; Woodhead A; Schiemann AH; Stowell KM
    Anaesth Intensive Care; 2019 Jan; 47(1):60-68. PubMed ID: 30864471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update.
    Patil PM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Sep; 112(3):e1-7. PubMed ID: 21827956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.